Cylene Pharmaceuticals
Cylene Pharmaceuticals, Inc. was founded to develop targeted small-molecule drugs to treat life-threatening cancers. The company’s lead drug was CX-3543, which was developed through Phase II clinical trials.
Investors
- Research Corporation Technologies
- Sanderling Ventures
- Novartis BioVentures
- IngleWood Ventures
- Coastview Capital
- BioVentures Investors
- Mitsui & Co. Venture Partners
- Morningside Venture Investments
- TDL Investors
- William Harris Investors
- Lakeview Capital
- The Viterbi Group
- HBM BioVentures
- Lilly Ventures.
Inventors/Founders
- Laurence Hurley, Ph.D., D.Sc.
University of Arizona
(Hurley discovered and initially developed the Cylene technologies while at the University of Texas at Austin) - Daniel D. Von Hoff, M.D.
Unversity of Arizona